Business
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia
Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine Findings also support use of speech latency as an enrichment tool that can reduce sample-size and enhance outcomes in clinical trials for schizophrenia CUPERTINO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage
About this update from Reviva Pharmaceuticals Holdings, Inc.
[{"type":"image","alt":"Reviva Pharmaceuticals","displaySize":"","headline":null,"caption":"Reviva Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/41c0f5cc737db653c49d46fe5ad892c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D8sDX1mL7wV8j6M4A9rWcA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/41c0f5cc737db653c49d46fe5ad892c8","width":300,"height":138}},"lazy":false},{"type":"text","content":"Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine","length":200,"tagName":"p"},{"type":"text","content":"Findings also support use of speech latency as an enrichment tool that can reduce sample-size and enhance outcomes in clinical trials for schizophrenia","length":151,"tagName":"p"},{"type":"text","content":"CUPERTINO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the publication, in the peer-reviewed journal Biological Psychiatry, of an article entitled A Single, Interpretable Vocal Biomarker for Enriching Antipsychotic Clinical Trials that highlights clinical vocal biomarker data from the RECOVER Phase 3 clinical trial and the therapeutic potential of brilaroxazine for the treatment of schizophrenia. The publication is available at revivapharma.com/publications.","length":745,"tagName":"p"},{"type":"text","content":"“Publication of our vocal biomarker findings from our RECOVER Phase 3 trial in this top-tier, peer-reviewed journal underscores the robustness of our clinical data and the differentiated therapeutic potential of brilaroxazine to address unmet needs in schizophrenia and its major symptom domain negative symptoms,” said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. “These results show speech latency as a scalable, objective biomarker that can be used to evaluate brilaroxazine’s effect on negative symptoms and other core domains of schizophrenia, a...